Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?
Jonas Bergh(Karolinska Institutet), Thomas Hatschek(Karolinska University Hospital), Yvonne Brandberg(Karolinska Institutet), Zakaria Einbeigi(Sahlgrenska University Hospital), Tobias Lekberg(Karolinska University Hospital), Erika Isaksson-Friman(Saint Göran Hospital), Ana Bosch(Memorial Sloan Kettering Cancer Center), Lena Carlsson(University of Gothenburg), Theodoros Foukakis(Karolinska Institutet), Mats Hellström(Karolinska University Hospital), Claudia Maes(Karolinska University Hospital), Henrik Lindman(Uppsala University), Hemming Johansson(Karolinska Institutet), Anne Andersson(Umeå University), Judith Bjöhle(Karolinska University Hospital), Hanna Fredholm(Karolinska University Hospital), Ann Charlotte Dreifaldt(Örebro University Hospital), Ellinor Elinder(Stockholm South General Hospital)
Cited by 21
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
|New England Journal of Medicine|2007|4.6k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k